newsNovartis’ new acquisition aims to advance first-in-class STING treatments for…
19 March 2024 | By Catherine Eckford (European Pharmaceutical Review)
Novartis’ new acquisition aims to advance first-in-class STING treatments for inflammation-driven diseases.